公开(公告)号：US10807987B2

公开(公告)日：2020-10-20

申请号：US16366710

申请日：2019-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Satoshi Mikami ,  Masaki Seto ,  Shinji Morimoto ,  Shinji Nakamura ,  Sachie Takashima ,  Masataka Murakami ,  Masaki Daini ,  Makoto Kamata ,  Minoru Nakamura ,  Yasufumi Wada ,  Hiroyuki Kakei ,  Kazuaki Takami ,  Taisuke Tawaraishi ,  Jumpei Aida ,  Kouichi Iwanaga ,  Satoshi Yamamoto

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US09527841B2

公开(公告)日：2016-12-27

申请号：US14414020

申请日：2013-07-12

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinji Nakamura ,  Satoshi Mikami ,  Kawasaki Masanori ,  Izumi Nomura ,  Tomoko Ashizawa ,  Takahiko Taniguchi

IPC: C07D241/38 ,  C07D471/04 ,  C07D235/16

CPC classification number: C07D471/04 ,  C07D235/16

Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

Abstract translation: 本发明提供具有PDE2A选择性抑制作用的化合物，其可用作预防或治疗精神分裂症，阿尔茨海默氏病等。 本发明是由式（1）表示的化合物：其中每个符号如说明书中所述或其盐。

公开(公告)号：US09469637B2

公开(公告)日：2016-10-18

申请号：US14397066

申请日：2013-04-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi Mikami ,  Shinji Nakamura ,  Tomoko Ashizawa ,  Shigekazu Sasaki ,  Takahiko Taniguchi ,  Izumi Nomura ,  Masanori Kawasaki

IPC: C07D241/36 ,  C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K9/20 ,  A61K31/498 ,  A61K31/555 ,  C07D519/00 ,  C07F7/1804

Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US11702419B2

公开(公告)日：2023-07-18

申请号：US17201878

申请日：2021-03-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Satoshi Mikami ,  Masaki Seto ,  Shinji Morimoto ,  Shinji Nakamura ,  Sachie Takashima ,  Masataka Murakami ,  Masaki Daini ,  Makoto Kamata ,  Minoru Nakamura ,  Yasufumi Wada ,  Hiroyuki Kakei ,  Kazuaki Takami ,  Taisuke Tawaraishi ,  Jumpei Aida ,  Kouichi Iwanaga ,  Satoshi Yamamoto

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

CPC classification number: C07D487/04 ,  A61K9/2095 ,  A61K9/4833 ,  A61P25/00 ,  C07D471/04

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US11059780B2

公开(公告)日：2021-07-13

申请号：US16491811

申请日：2018-03-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masaki Daini ,  Yuhei Miyanohana ,  Satoshi Mikami ,  Yuichi Kajita ,  Masaki Ogino ,  Tatsuki Koike ,  Kohei Takeuchi

IPC: C07D207/12 ,  C07D405/12 ,  C07D403/12 ,  C07D405/14 ,  C07D401/14 ,  C07D417/14 ,  C07D403/14 ,  C07D493/08 ,  C07D487/10 ,  C07D498/10 ,  C07D471/04 ,  C07D413/12 ,  C07D491/107 ,  C07D487/08

Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20160159808A1

公开(公告)日：2016-06-09

申请号：US14907139

申请日：2014-07-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masanori Kawasaki ,  Satoshi Mikami ,  Shinji Nakamura ,  Nobuyuki Negoro ,  Shuhei Ikeda ,  Izumi Nomura ,  Tomoko Ashizawa ,  Toshihiro Imaeda ,  Masaki Seto ,  Shigekazu Sasaki ,  Shogo Marui ,  Takahiko Taniguchi

IPC: C07D487/04 ,  C07D498/08 ,  C07D491/08 ,  C07D471/04 ,  C07D473/00

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D473/00 ,  C07D491/08 ,  C07D498/08

Abstract: A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like.

Abstract translation: 由式（I）表示的化合物：其中每个符号如说明书所述，或其盐具有PDE2A抑制作用，并且可用作精神分裂症，阿尔茨海默氏病等的预防或治疗药物。

公开(公告)号：US11939327B2

公开(公告)日：2024-03-26

申请号：US17819818

申请日：2022-08-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tomoaki Hasui ,  Shinji Nakamura ,  Satoshi Mikami ,  Tohru Yamashita

IPC: C07D471/04 ,  C07D407/12 ,  C07D413/10 ,  C07D413/14

CPC classification number: C07D471/04 ,  C07D407/12 ,  C07D413/10 ,  C07D413/14

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US11459325B2

公开(公告)日：2022-10-04

申请号：US16961476

申请日：2019-01-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuta Tanaka ,  Tomohiro Ohashi ,  Zenichi Ikeda ,  Yuta Tanaka ,  Florian Pünner ,  Takeshi Yamamoto ,  Keiko Kakegawa ,  Fumiaki Kikuchi ,  Nao Morishita ,  Takahito Kasahara ,  Masaki Seto ,  Minoru Nakamura ,  Kazuaki Takami ,  Masataka Murakami ,  Masaki Daini ,  Satoshi Mikami ,  Minoru Sasaki

IPC: C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  A61P25/28

Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US11447488B2

公开(公告)日：2022-09-20

申请号：US16753630

申请日：2018-10-04

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tomoaki Hasui ,  Shinji Nakamura ,  Satoshi Mikami ,  Tohru Yamashita

IPC: C07D471/04 ,  C07D407/12 ,  C07D413/10 ,  C07D413/14

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US11407748B2

公开(公告)日：2022-08-09

申请号：US16753613

申请日：2018-10-04

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinji Nakamura ,  Satoshi Mikami ,  Tomoaki Hasui ,  Tohru Yamashita ,  Shinji Morimoto ,  Hidekazu Tokuhara ,  Norio Oyabu ,  Masami Yamada ,  Atsuko Ochida ,  Kazuaki Takami ,  Xin Liu

IPC: A61K31/519 ,  C07D471/04 ,  C07D487/04 ,  A61K9/20 ,  C07D519/00

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.